Correction: The potent human CAR activator CITCO is a non-genotoxic hepatic tumour-promoting agent in humanised constitutive androstane receptor mice but not in wild-type animals - Scorecard - MDSpire

Correction: The potent human CAR activator CITCO is a non-genotoxic hepatic tumour-promoting agent in humanised constitutive androstane receptor mice but not in wild-type animals

  • By

  • C. J. Henderson

  • A. W. McLaren

  • A. K. MacLeod

  • D. Lin

  • A. R. Cameron

  • L. R. Chatham

  • J. Moggs

  • F. Inesta‑Vaquera

  • John P. Thomson

  • Richard R. Meehan

  • P. Chakravarty

  • M. Schwarz

  • C. Roland Wolf

  • June 27, 2026

  • 0 min

Share

Clinical Scorecard: Correction: The strong human CAR activator CITCO acts as a non-genotoxic promoter of liver tumors in humanized constitutive androstane receptor mice, unlike in wild-type counterparts

At a Glance

CategoryDetail
ConditionLiver Tumors
Key MechanismsActivation of human CAR by CITCO
Target PopulationHumanized constitutive androstane receptor mice
Care SettingToxicology research

Key Highlights

  • CITCO acts as a non-genotoxic promoter of liver tumors
  • Study involves humanized CAR mice models
  • Correction regarding image reuse from prior publication
  • No impact on results or conclusions of the original article

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

        Risks

          Patient & Prescribing Data

          Clinical Best Practices

            Related Resources & Content

            Original Source(s)

            Correction: The potent human CAR activator CITCO is a non-genotoxic hepatic tumour-promoting agent in humanised constitutive androstane receptor mice but not in wild-type animals

            • by C. J. Henderson, A. W. McLaren, A. K. MacLeod, D. Lin, A. R. Cameron, L. R. Chatham, J. Moggs, F. Inesta‑Vaquera, John P. Thomson, Richard R. Meehan, P. Chakravarty, M. Schwarz, C. Roland Wolf

            • June 27, 2026

            Related Content

            ESMO Breast Cancer 2026 Highlights Panel Discussion

            Harold Burstein, MD, PhD; Sara Tolaney, MD, MPH; Erica L. Mayer, MD, MPH; Nancy Lin, MD; and Ana C. Garrido-Castro, MD discuss important breast cancer research presented at the 2026 ESMO Breast Cancer Congress.

            • June 26, 2026

            • 1 min
            Quercetagetin-rich flavonoids from marigold induce apoptosis inhibit metastasis of non-small cell lung cancer via the p53/p21 signaling pathway

            Solution for the hot spots in adaptive radiotherapy planning for cervical cancer: a case report and review of literature